The sales of antiarrhythmic medicines in Germany are projected to decline from USD 74.2 million in 2024 to USD 70.3 million by 2028. From 2023 to 2024, the industry saw no growth as it stabilized at USD 74.2 million. However, from 2024 onwards, sales demonstrate a decreasing trend: 1.75% drop in 2025, 1.51% in 2026, 1.11% in 2027, and 0.99% in 2028. On a compounded annual growth rate (CAGR) basis, the average yearly decline over the five-year forecast period is approximately 1.34%.

Future trends to watch for:

Innovation and introduction of new pharmaceuticals addressing arrhythmia.
Impact of generic medicine availability and its market penetration.
Changes in healthcare policies and reimbursement scenarios.
Advancements in alternative treatments, such as surgical procedures and lifestyle changes.